Co-Authors
This is a "connection" page, showing publications co-authored by ROBERT ORLOWSKI and FELIPE SAMANIEGO.
Connection Strength
0.175
-
Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat. Cancer Drug Resist. 2021; 4(4):888-902.
Score: 0.050
-
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018 06 15; 124(12):2561-2569.
Score: 0.040
-
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov; 15(12):1311-8.
Score: 0.031
-
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec; 163(5):611-20.
Score: 0.029
-
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012 Jun; 23(6):1640-5.
Score: 0.025